Opioid-Induced Constipation (OIC) Treatment Market Report

Japan Opioid-Induced Constipation (OIC) Treatment Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Oct 24, 2019
  • PAGES：188
  • REPORT CODE：GMM348228
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan Opioid-Induced Constipation (OIC) Treatment market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan Opioid-Induced Constipation (OIC) Treatment market. Detailed analysis of key players, along with key growth strategies adopted by Opioid-Induced Constipation (OIC) Treatment industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Salix Pharmaceuticals, Inc.

    • Takeda Pharmaceutical Company Limited.

    • Cubist Pharmaceuticals.

    • S.L.A. Pharma AG

    • AIKO Biotechnology.

    • AstraZeneca plc, Inc

    • Pfizer, Inc

    • SLA Pharma AG

    By Type:

    • Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA)

    • Non-selective opioid antagonist

    • μ-Opioid antagonist

    • Locally Acting Chloride Channel Activator (LACCA)

    By End-User:

    • Drug store

    • Independent Pharmacies

    • Hospital Pharmacies

    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Opioid-Induced Constipation (OIC) Treatment Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA) from 2014 to 2026

      • 1.3.2 Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Non-selective opioid antagonist from 2014 to 2026

      • 1.3.3 Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of μ-Opioid antagonist from 2014 to 2026

      • 1.3.4 Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Locally Acting Chloride Channel Activator (LACCA) from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Drug store from 2014 to 2026

      • 1.4.2 Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Independent Pharmacies from 2014 to 2026

      • 1.4.3 Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Opioid-Induced Constipation (OIC) Treatment Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Opioid-Induced Constipation (OIC) Treatment by Major Types

      • 3.4.1 Market Size and Growth Rate of Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA)

      • 3.4.2 Market Size and Growth Rate of Non-selective opioid antagonist

      • 3.4.3 Market Size and Growth Rate of μ-Opioid antagonist

      • 3.4.4 Market Size and Growth Rate of Locally Acting Chloride Channel Activator (LACCA)

    4 Segmentation of Opioid-Induced Constipation (OIC) Treatment Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Opioid-Induced Constipation (OIC) Treatment by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Opioid-Induced Constipation (OIC) Treatment in Drug store

      • 4.4.2 Market Size and Growth Rate of Opioid-Induced Constipation (OIC) Treatment in Independent Pharmacies

      • 4.4.3 Market Size and Growth Rate of Opioid-Induced Constipation (OIC) Treatment in Hospital Pharmacies

    5 Market Analysis by Regions

    • 5.1 Japan Opioid-Induced Constipation (OIC) Treatment Production Analysis by Regions

    • 5.2 Japan Opioid-Induced Constipation (OIC) Treatment Consumption Analysis by Regions

    6 Hokkaido Opioid-Induced Constipation (OIC) Treatment Landscape Analysis

    • 6.1 Hokkaido Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major Types

    • 6.2 Hokkaido Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major End-Users

    7 Tohoku Opioid-Induced Constipation (OIC) Treatment Landscape Analysis

    • 7.1 Tohoku Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major Types

    • 7.2 Tohoku Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major End-Users

    8 Kanto Opioid-Induced Constipation (OIC) Treatment Landscape Analysis

    • 8.1 Kanto Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major Types

    • 8.2 Kanto Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major End-Users

    9 Chubu Opioid-Induced Constipation (OIC) Treatment Landscape Analysis

    • 9.1 Chubu Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major Types

    • 9.2 Chubu Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major End-Users

    10 Kinki Opioid-Induced Constipation (OIC) Treatment Landscape Analysis

    • 10.1 Kinki Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major Types

    • 10.2 Kinki Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major End-Users

    11 Chugoku Opioid-Induced Constipation (OIC) Treatment Landscape Analysis

    • 11.1 Chugoku Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major Types

    • 11.2 Chugoku Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major End-Users

    12 Shikoku Opioid-Induced Constipation (OIC) Treatment Landscape Analysis

    • 12.1 Shikoku Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major Types

    • 12.2 Shikoku Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major End-Users

    13 Kyushu Opioid-Induced Constipation (OIC) Treatment Landscape Analysis

    • 13.1 Kyushu Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major Types

    • 13.2 Kyushu Opioid-Induced Constipation (OIC) Treatment Landscape Analysis by Major End-Users

    14 Major Players Profiles

    • 14.1 Salix Pharmaceuticals, Inc.

      • 14.1.1 Salix Pharmaceuticals, Inc. Company Profile and Recent Development

      • 14.1.2 Market Performance

      • 14.1.3 Product and Service Introduction

    • 14.2 Takeda Pharmaceutical Company Limited.

      • 14.2.1 Takeda Pharmaceutical Company Limited. Company Profile and Recent Development

      • 14.2.2 Market Performance

      • 14.2.3 Product and Service Introduction

    • 14.3 Cubist Pharmaceuticals.

      • 14.3.1 Cubist Pharmaceuticals. Company Profile and Recent Development

      • 14.3.2 Market Performance

      • 14.3.3 Product and Service Introduction

    • 14.4 S.L.A. Pharma AG

      • 14.4.1 S.L.A. Pharma AG Company Profile and Recent Development

      • 14.4.2 Market Performance

      • 14.4.3 Product and Service Introduction

    • 14.5 AIKO Biotechnology.

      • 14.5.1 AIKO Biotechnology. Company Profile and Recent Development

      • 14.5.2 Market Performance

      • 14.5.3 Product and Service Introduction

    • 14.6 AstraZeneca plc, Inc

      • 14.6.1 AstraZeneca plc, Inc Company Profile and Recent Development

      • 14.6.2 Market Performance

      • 14.6.3 Product and Service Introduction

    • 14.7 Pfizer, Inc

      • 14.7.1 Pfizer, Inc Company Profile and Recent Development

      • 14.7.2 Market Performance

      • 14.7.3 Product and Service Introduction

    • 14.8 SLA Pharma AG

      • 14.8.1 SLA Pharma AG Company Profile and Recent Development

      • 14.8.2 Market Performance

      • 14.8.3 Product and Service Introduction

     

    The List of Tables and Figures (Totals 125 Figures and 179 Tables)

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA) from 2014 to 2026

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Non-selective opioid antagonist from 2014 to 2026

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of μ-Opioid antagonist from 2014 to 2026

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Locally Acting Chloride Channel Activator (LACCA) from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Drug store from 2014 to 2026

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Independent Pharmacies from 2014 to 2026

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Opioid-Induced Constipation (OIC) Treatment Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Opioid-Induced Constipation (OIC) Treatment

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Opioid-Induced Constipation (OIC) Treatment by Different Types from 2014 to 2026

    • Table Consumption Share of Opioid-Induced Constipation (OIC) Treatment by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA)

    • Figure Market Size and Growth Rate of Non-selective opioid antagonist

    • Figure Market Size and Growth Rate of μ-Opioid antagonist

    • Figure Market Size and Growth Rate of Locally Acting Chloride Channel Activator (LACCA)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Opioid-Induced Constipation (OIC) Treatment by Different End-Users from 2014 to 2026

    • Table Consumption Share of Opioid-Induced Constipation (OIC) Treatment by Different End-Users from 2014 to 2026

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Drug store from 2014 to 2026

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Independent Pharmacies from 2014 to 2026

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • Table Japan Opioid-Induced Constipation (OIC) Treatment Production by Regions

    • Table Japan Opioid-Induced Constipation (OIC) Treatment Production Share by Regions

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Production Share by Regions in 2014

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Production Share by Regions in 2018

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Production Share by Regions in 2026

    • Table Japan Opioid-Induced Constipation (OIC) Treatment Consumption by Regions

    • Table Japan Opioid-Induced Constipation (OIC) Treatment Consumption Share by Regions

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Consumption Share by Regions in 2014

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Consumption Share by Regions in 2018

    • Figure Japan Opioid-Induced Constipation (OIC) Treatment Consumption Share by Regions in 2026

    • Table Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption by Types from 2014 to 2026

    • Table Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2014

    • Figure Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2018

    • Figure Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2026

    • Table Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption by End-Users from 2014 to 2026

    • Table Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2014

    • Figure Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2018

    • Figure Hokkaido Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2026

    • Table Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption by Types from 2014 to 2026

    • Table Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types from 2014 to 2026

    • Figure Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2014

    • Figure Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2018

    • Figure Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2026

    • Table Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption by End-Users from 2014 to 2026

    • Table Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2014

    • Figure Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2018

    • Figure Tohoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2026

    • Table Kanto Opioid-Induced Constipation (OIC) Treatment Consumption by Types from 2014 to 2026

    • Table Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types from 2014 to 2026

    • Figure Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2014

    • Figure Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2018

    • Figure Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2026

    • Table Kanto Opioid-Induced Constipation (OIC) Treatment Consumption by End-Users from 2014 to 2026

    • Table Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2014

    • Figure Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2018

    • Figure Kanto Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2026

    • Table Chubu Opioid-Induced Constipation (OIC) Treatment Consumption by Types from 2014 to 2026

    • Table Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types from 2014 to 2026

    • Figure Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2014

    • Figure Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2018

    • Figure Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2026

    • Table Chubu Opioid-Induced Constipation (OIC) Treatment Consumption by End-Users from 2014 to 2026

    • Table Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2014

    • Figure Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2018

    • Figure Chubu Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2026

    • Table Kinki Opioid-Induced Constipation (OIC) Treatment Consumption by Types from 2014 to 2026

    • Table Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types from 2014 to 2026

    • Figure Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2014

    • Figure Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2018

    • Figure Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2026

    • Table Kinki Opioid-Induced Constipation (OIC) Treatment Consumption by End-Users from 2014 to 2026

    • Table Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2014

    • Figure Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2018

    • Figure Kinki Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2026

    • Table Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption by Types from 2014 to 2026

    • Table Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types from 2014 to 2026

    • Figure Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2014

    • Figure Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2018

    • Figure Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2026

    • Table Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption by End-Users from 2014 to 2026

    • Table Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2014

    • Figure Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2018

    • Figure Chugoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2026

    • Table Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption by Types from 2014 to 2026

    • Table Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types from 2014 to 2026

    • Figure Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2014

    • Figure Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2018

    • Figure Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2026

    • Table Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption by End-Users from 2014 to 2026

    • Table Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2014

    • Figure Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2018

    • Figure Shikoku Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2026

    • Table Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption by Types from 2014 to 2026

    • Table Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types from 2014 to 2026

    • Figure Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2014

    • Figure Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2018

    • Figure Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Share by Types in 2026

    • Table Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption by End-Users from 2014 to 2026

    • Table Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2014

    • Figure Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2018

    • Figure Kyushu Opioid-Induced Constipation (OIC) Treatment Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of Salix Pharmaceuticals, Inc.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Salix Pharmaceuticals, Inc.

    • Figure Sales and Growth Rate Analysis of Salix Pharmaceuticals, Inc.

    • Figure Revenue and Market Share Analysis of Salix Pharmaceuticals, Inc.

    • Table Product and Service Introduction of Salix Pharmaceuticals, Inc.

    • Table Company Profile and Development Status of Takeda Pharmaceutical Company Limited.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda Pharmaceutical Company Limited.

    • Figure Sales and Growth Rate Analysis of Takeda Pharmaceutical Company Limited.

    • Figure Revenue and Market Share Analysis of Takeda Pharmaceutical Company Limited.

    • Table Product and Service Introduction of Takeda Pharmaceutical Company Limited.

    • Table Company Profile and Development Status of Cubist Pharmaceuticals.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Cubist Pharmaceuticals.

    • Figure Sales and Growth Rate Analysis of Cubist Pharmaceuticals.

    • Figure Revenue and Market Share Analysis of Cubist Pharmaceuticals.

    • Table Product and Service Introduction of Cubist Pharmaceuticals.

    • Table Company Profile and Development Status of S.L.A. Pharma AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of S.L.A. Pharma AG

    • Figure Sales and Growth Rate Analysis of S.L.A. Pharma AG

    • Figure Revenue and Market Share Analysis of S.L.A. Pharma AG

    • Table Product and Service Introduction of S.L.A. Pharma AG

    • Table Company Profile and Development Status of AIKO Biotechnology.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AIKO Biotechnology.

    • Figure Sales and Growth Rate Analysis of AIKO Biotechnology.

    • Figure Revenue and Market Share Analysis of AIKO Biotechnology.

    • Table Product and Service Introduction of AIKO Biotechnology.

    • Table Company Profile and Development Status of AstraZeneca plc, Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca plc, Inc

    • Figure Sales and Growth Rate Analysis of AstraZeneca plc, Inc

    • Figure Revenue and Market Share Analysis of AstraZeneca plc, Inc

    • Table Product and Service Introduction of AstraZeneca plc, Inc

    • Table Company Profile and Development Status of Pfizer, Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer, Inc

    • Figure Sales and Growth Rate Analysis of Pfizer, Inc

    • Figure Revenue and Market Share Analysis of Pfizer, Inc

    • Table Product and Service Introduction of Pfizer, Inc

    • Table Company Profile and Development Status of SLA Pharma AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of SLA Pharma AG

    • Figure Sales and Growth Rate Analysis of SLA Pharma AG

    • Figure Revenue and Market Share Analysis of SLA Pharma AG

    • Table Product and Service Introduction of SLA Pharma AG

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US